OpenNashEarnings

Health Insurance · NYSE: HUM

Humana earnings: results, call transcripts & KPI history

2 quarters · fiscal year ends December · next results expected around 10 Feb 2027

Investor relations ↗SEC filings ↗KPIs as CSV

Latest: Q3 2026

Humana's Bonus Year 2028 Star Ratings came in well above its top-quartile goal, and early 2027 enrollment signals are strong as CenterWell Primary Care and Medicaid keep expanding.

Humana's individual Medicare Advantage, stand-alone Part D, Medicaid and CenterWell businesses all grew this year. CenterWell Primary Care added 146,800 patients, or 30%, partly through the MaxHealth acquisition. Medicaid grew through new integrated dual-eligible programs in Michigan, Illinois and South Carolina. Pharmacy grew through Humana's own members and more non-Humana clients. A new BlackRock joint venture replaced the Welsh, Carson, Anderson & Stowe joint ventures that fund Primary Care clinics.

Read the Q3 2026 summary →

Quarters

KPI history

Revenue$41.2B+26.1% y/yQ3 2026
Q4 2024: $29.2B (worked out from the annual figure)Q4 ’24$29.2BQ1 2025: $32.1BQ1 ’25$32.1BQ2 2025: $32.4BQ2 ’25$32.4BQ3 2025: $32.6BQ3 ’25$32.6BQ4 2025: $32.5B (worked out from the annual figure)Q4 ’25$32.5BQ1 2026: $39.6BQ1 ’26$39.6BQ2 2026: $40.9BQ2 ’26$40.9BQ3 2026: $41.2BQ3 ’26$41.2B

Fourth quarter worked out from the annual figure.

Data
Q4 2024$29.2B *
Q1 2025$32.1B
Q2 2025$32.4B
Q3 2025$32.6B
Q4 2025$32.5B *
Q1 2026$39.6B
Q2 2026$40.9B
Q3 2026$41.2B
Diluted EPS (GAAP)$1.33−17.9% y/yQ3 2026
Q1 2025: $10.30Q1 ’25$10.30Q2 2025: $4.51Q2 ’25$4.51Q3 2025: $1.62Q3 ’25$1.62Q1 2026: $9.83Q1 ’26$9.83Q2 2026: $5.73Q2 ’26$5.73Q3 2026: $1.33Q3 ’26$1.33
Data
Q1 2025$10.30
Q2 2025$4.51
Q3 2025$1.62
Q1 2026$9.83
Q2 2026$5.73
Q3 2026$1.33

Fourth-quarter EPS appears once the press release is read; filings report it only for the full year.

Operating margin0.2%−1.0 pts y/yQ3 2026
Q4 2024: -1.9%Q4 ’24-1.9%Q1 2025: 6.3%Q1 ’256.3%Q2 2025: 3.4%Q2 ’253.4%Q3 2025: 1.2%Q3 ’251.2%Q4 2025: -2.5%Q4 ’25-2.5%Q1 2026: 4.4%Q1 ’264.4%Q2 2026: 3.3%Q2 ’263.3%Q3 2026: 0.2%Q3 ’260.2%
Data
Q4 2024-1.9%
Q1 20256.3%
Q2 20253.4%
Q3 20251.2%
Q4 2025-2.5%
Q1 20264.4%
Q2 20263.3%
Q3 20260.2%
Free cash flow$2.0B+142.3% y/yQ3 2026
Q4 2024: -$682.0MQ4 ’24-$682.0MQ1 2025: $236.0MQ1 ’25$236.0MQ2 2025: $1.2BQ2 ’25$1.2BQ3 2025: $836.0MQ3 ’25$836.0MQ4 2025: -$1.9BQ4 ’25-$1.9BQ1 2026: $1.1BQ1 ’26$1.1BQ2 2026: $1.8BQ2 ’26$1.8BQ3 2026: $2.0BQ3 ’26$2.0B
Data
Q4 2024-$682.0M
Q1 2025$236.0M
Q2 2025$1.2B
Q3 2025$836.0M
Q4 2025-$1.9B
Q1 2026$1.1B
Q2 2026$1.8B
Q3 2026$2.0B

Operating cash flow minus capital expenditure, from cash flow statements.

Q4 2024Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026Q2 2026Q3 2026
Revenue$29.2Bd$32.1B$32.4B$32.6B$32.5Bd$39.6B$40.9B$41.2B
Operating income-$543.0Md$2.0B$1.1B$400.0M-$808.0Md$1.8B$1.4B$75.0M
Operating margin-1.9%6.3%3.4%1.2%-2.5%4.4%3.3%0.2%
Net income-$693.0Md$1.2B$545.0M$195.0M-$796.0Md$1.2B$694.0M$162.0M
Diluted EPS—$10.30$4.51$1.62—$9.83$5.73$1.33
Operating cash flow-$528.0Md$331.0M$1.3Bd$971.0Md-$1.7Bd$1.3B$2.0Bd$2.2Bd
Capital expenditure$154.0Md$95.0M$114.0Md$135.0Md$202.0Md$121.0M$132.0Md$137.0Md
Free cash flow-$682.0M$236.0M$1.2B$836.0M-$1.9B$1.1B$1.8B$2.0B

From XBRL data in 10-Q and 10-K filings. d derived: a fourth quarter is the full year minus the first nine months, and cash flows are year-to-date figures differenced.

10-K and 10-Q filings